Vatreptacog alfa

DB12409InvestigationalProtein Based Therapies

Vatreptacog Alfa (Activated) has been used in trials studying the treatment of Haemophilia B, Haemophilia A, Congenital Bleeding Disorder, Haemophilia A With Inhibitors, and Haemophilia B With Inhibitors.

Mechanism: Pharmacologically active on Coagulation factor VII
Curator reviewed
Also known as: Vatreptacog alfa (activated)

Resolves to

Compound

UNII2F6ZF5WYCCCAS897936-89-9

Targets

P08709F7

What you can answer from here — as of July 07, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

92Drug interactionsStructured to mechanism, not free text

3Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Vatreptacog alfa, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account